$3.90
6.02% yesterday
Nasdaq, Dec 24, 10:11 pm CET
ISIN
US60855D1019
Symbol
MBRX

Moleculin Biotech, Inc. Stock price

$3.90
-5.25 57.39% 1M
-3.69 48.60% 6M
-38.60 90.82% YTD
-41.60 91.43% 1Y
-449.85 99.14% 3Y
-1,953.83 99.80% 5Y
-17,996.10 99.98% 10Y
-17,996.10 99.98% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.25 6.02%
ISIN
US60855D1019
Symbol
MBRX
Industry

Key metrics

Basic
Market capitalization
$8.1m
Enterprise Value
$1.4m
Net debt
positive
Cash
$6.7m
Shares outstanding
2.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
35.3%
Return on Equity
-364.0%
ROCE
-165.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-24.1m | $-33.8m
EBIT
$-24.2m | $-27.8m
Net Income
$-41.4m | $-60.6m
Free Cash Flow
$-22.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
16.3% | -27.4%
EBIT
16.3% | -4.5%
Net Income
-37.2% | -178.5%
Free Cash Flow
7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-27.7
FCF per Share
$-11.3
Short interest
18.0%
Employees
17
Rev per Employee
$0.0
Show more

Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Moleculin Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Moleculin Biotech, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Moleculin Biotech, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Moleculin Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.87 8.87
0% 0%
-
- Research and Development Expense 15 15
24% 24%
-
-24 -24
16% 16%
-
- Depreciation and Amortization 0.11 0.11
15% 15%
-
EBIT (Operating Income) EBIT -24 -24
16% 16%
-
Net Profit -41 -41
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moleculin Biotech, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight
Neutral
GlobeNewsWire
15 days ago
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purch...
Neutral
GlobeNewsWire
16 days ago
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range
More Moleculin Biotech, Inc. News

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Head office United States
CEO Walter Klemp
Employees 17
Founded 2015
Website moleculin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today